Table 1.

Autophagy inhibitors in cancer cells.

Autophagy inhibitor	Target point	Inhibition stage	References
3-MA	PI3K inhibition	Early	(Horwacik et al., 2015; Zhang et al., 2015)
LY294002	PI3K/mTOR inhibition	Early	(Feng et al., 2018; Shen et al., 2017)
Baf A1	Vacuolar-type H(+)-ATPase inhibition	Late	(Miyazawa, 2011)
CQ	Lysosomal inhibition	Late	(Kimura et al., 2012; Fukuda et al., 2015; Liu et al., 2016)
HCQ	Lysosomal inhibition	Late	(Vogl et al., 2014; Rangwala et al., 2014)
ABT-737	Bcl-2 inhibition	Early	(Huang and Sinicrope, 2010; Yang et al., 2016)
Obatoclax	Lysosomal inhibition	Late	(Koehler et al., 2015; Jiménez-Guerrero et al., 2018)
Clarithromycin	Block autophagy flux	Late	(Altman and Platanias, 2012; Sugita et al., 2015)
Resveratrol	Autophagy regulator -S6K1	Early	(Lin et al., 2012; Alayev et al., 2015; Rai et al., 2016)
Quinacrine	Lysosomal inhibition	Late	(Lobo et al., 2013; Golden et al., 2015)
4-Acetylantroquinonol B	Block autophagy flux	Late	(Liu et al., 2017)
EGCG	Block autophagy flux	Late	(Meng et al., 2019)

3-MA, 3-methyladenine; Baf A1, bafilomycin A1; PI3K, phosphatidylinositol 3 kinase; mTOR, mammalian target of rapamycin; CQ, chloroquine; HCQ, hydroxychloroquine; ATPase, adenosine triphosphatase; EGCG, Epigallocatechin gallate.